PsyMuKB

PPI network (data source: BioGrid)

A gene is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the mean normalized expression(base 2 log of (TPM+1)) +1 in all brain tissue from GTEx v7 or BrainSpan data.

A protein is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the normalized expression (base 10 log of iBAQ intensity) ≥0.5 in at least one brain tissue from ProteomicsDB data. Otherwise, a gene or protein is determined as either with below-cutoff expressions or no available data.

	The queried gene/protein
	The interacting partner is expressed at mRNA-level
	The interacting partner is expressed at protein-level
	The interacting partner is expressed at both mRNA and protein level
	The interacting partner is with either below-cutoff expressions or no expression data at both mRNA and protein level
	The interacting partner is hit by coding DNMs
	Physical interaction between queried gene/protein and its partner
	Physical interaction between two interacting partners

Symbol A	GeneA coding DNM count	Symbol B	GeneB coding DNM count	Interaction detection method	Publication	Evidence
MAP2K6	2	MAPK14	0	enzymatic study, enzymatic study, enzymatic study, enzymatic study, affinity chromatography technology, pull down, enzymatic study, fluorescent resonance energy transfe	Sanz-Moreno V (2003), Raingeaud J (1996), Stein B (1996), Chen Z (2001), Casar B (2007), Xia Y (1998), ter Haar E (2007), Ivanov AA (2017)	8
PLCB2	0	MAP2K3	1	two hybrid, affinity chromatography technology	Barr AJ (2002), Barr AJ (2002)	2
PLCB2	0	GNAQ	1	affinity chromatography technology	Cartier A (2011)	1
PLCB2	0	TBXA2R	1	affinity chromatography technology	Cartier A (2011)	1
WDR26	6	PLCB2	0	affinity chromatography technology	Sun Z (2013)	1
PLCB2	0	PLCB2	0	unspecified method	Singer AU (2002)	1
MAP2K3	1	MAP2K6	2	genetic interference, affinity chromatography technology, imaging technique, affinity chromatography technology, fluorescent resonance energy transfe	Huber TB (2001), Huttlin EL (2015), Chen TC (2014), Huttlin EL (2017), Ivanov AA (2017)	5
ALK	8	PLCB2	0	affinity chromatography technology	Crockett DK (2004)	1
PLCB2	0	WDR36	0	affinity chromatography technology	Cartier A (2011)	1
TBXA2R	1	WDR36	0	two hybrid, pull down, affinity chromatography technology, affinity chromatography technology	Cartier A (2011), Cartier A (2011), Cartier A (2011), Cartier A (2011)	4
PLCB2	0	SLC9A3R2	8	affinity chromatography technology	Hwang JI (2000)	1
SNCA	0	PLCB2	0	pull down	Narayanan V (2005)	1
MAP2K3	1	MAPK14	0	enzymatic study, affinity chromatography technology, enzymatic study, enzymatic study, affinity chromatography technology, affinity chromatography technology, fluorescent resonance energy transfe, affinity chromatography technology, fluorescent resonance energy transfe	Chen Z (2001), Casar B (2007), Deacon K (1997), Mo JS (2010), Varjosalo M (2013), Huttlin EL (2015), Li L (2014), Huttlin EL (2017), Ivanov AA (2017)	9
PLCB2	0	MAPK14	0	affinity chromatography technology	Barr AJ (2002)	1
TBXA2R	1	GNAQ	1	fluorescent resonance energy transfe, affinity chromatography technology, pull down, x-ray crystallography, pull down, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology	Gales C (2005), Cartier A (2011), Chillar A (2010), Chillar A (2010), Manganello JM (2003), Theriault C (2004), Kelley LP (2003), Sikarwar AS (2013)	8
PLCB2	0	TRPM7	5	two hybrid, pull down, affinity chromatography technology	Runnels LW (2002), Runnels LW (2002), Runnels LW (2002)	3
WDR36	0	GNAQ	1	affinity chromatography technology	Cartier A (2011)	1
PLCB2	0	MAP2K6	2	affinity chromatography technology	Barr AJ (2002)	1